Drug Profile


Alternative Names: ROB 803

Latest Information Update: 09 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OxyPharma
  • Class Acetamides; Disease-modifying antirheumatics; Heterocyclic compounds with 4 or more rings; Small molecules
  • Mechanism of Action Cell differentiation modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Rheumatoid arthritis

Most Recent Events

  • 09 Feb 2016 Phase II development is ongoing in European Union, Georgia and Serbia and Montenegro
  • 30 Nov 2009 Efficacy, adverse events and drug interactions data from a phase II trial in Rheumatoid arthritis released by OxyPharma
  • 13 Aug 2009 OxyPharma completes a phase II trial in Rheumatoid arthritis in the EU, Serbia & Georgia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top